Intra-Cellular Therapies P/E Ratio

Intra-Cellular Therapies (ITCI) currently reports a P/E ratio of -183.15. That is below the Healthcare sector average of 26.85. Use the charts on this page to explore Intra-Cellular Therapies's P/E ratio history and peer comparisons.

Intra-Cellular Therapies's P/E ratio of -183.15 is lower than the Healthcare sector average of 26.85. That is roughly 782.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Intra-Cellular Therapies's market price to a fundamental measure such as earnings, sales, or book value. At -183.15, ITCI can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -183.15, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 26.85. From there, open related valuation or income-statement pages for Intra-Cellular Therapies, and consider following ITCI for alerts when major investors trade the stock.

Intra-Cellular Therapies is classified in the Healthcare sector. On P/E ratio, it currently shows -183.15 versus a sector average near 26.85. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ITCI with unrelated industries.